Industry experts share insights, best practices and the latest trends to assist you.
An in‑depth presentation of Miltenyi’s preclinical evaluation of BaEV‑pseudotyped lentiviral vector (BaEV‑LVV) engineered CAR‑NK cells and their translation into a clinical‑grade manufacturing platform for next‑generation cell therapies.
A comprehensive overview of Miltenyi Bioindustry’s end‑to‑end CDMO offerings - from early development through translational process development to GMP‑compliant manufacturing - designed to accelerate cell and gene therapy programs toward clinical and commercial readiness.
Learn how the BaEV (Baboon Envelope) lentiviral vector drives successful CAR-NK production, enabling efficient NK cell engineering and scalable clinical applications in cell and gene therapy.
Join industry leaders from Adaptimmune and Miltenyi Bioindustry as they share insights on the commercialization of lentiviral vectors as a drug substance. This webinar offers valuable lessons for advancing your biopharmaceutical projects.
The significant costs for manufacturing autologous cell therapies continue to create a major barrier to bringing these impactful medicines to more patients. This is primarily due to open process manipulations that require expensive engineering controls and extensive expenses for labor, equipment, materials, cleaning, validation, and a facility footprint. Join industry experts for this timely and important discussion on the use of a fully closed system design that enables commercial scale manufacturing in both centralized and point-of-care settings, and implementation in existing GMP environments.
Developing a cell therapy product is incredibly complex. Speed to clinic and market are imperative to reduce overall costs and maintain competitive market advantages. Leveraging an established lentiviral vector (LVV) process accelerates drug product development. Miltenyi Bioindustry’s LVV platform provides turnkey solutions for cell therapy developers. scalable preclinical batches, validated release assays, a fast-track to GMP manufacturing, and regulatory support.
Given the criticality and often underestimated role of analytics to address clinical and commercial manufacturing requirements, Miltenyi BioIndustry created centers of excellence focusing on analytics that work hand-in hand with process development and technology transfer groups using Miltenyi’s industry-leading cell processing and lentivirus manufacturing platforms.
Early, cross-functional Analytical Target Profile (ATP) planning – combined with locked hardware, software, and reagent platforms – turns assay validation into a smooth, predictable process. Miltenyi Bioindustry’s ASAT team standardizes gating, auto-aligns instruments with Smart Gain, and uses StainExpress™ panels to cut repeats and accelerate IND timelines.
A clinical-stage biotech company leveraged Miltenyi Bioindustry’s robust LVV platform to rapidly transition from preclinical development to GMP production. This case study showcases how a standardized, flexible process with built-in regulatory support can accelerate timelines, reduce risk, and ensure consistent, high-yield outcomes.
Discover how Miltenyi Bioindustry helped a biotech company enhance a bicistronic CAR construct by improving sequence stability and transduction efficiency. This case study highlights the power of molecular optimization and LVV platform integration to overcome recombination risks and accelerate clinical readiness.
Discover how Miltenyi Bioindustry helped automate and optimize an autologous cell therapy process, enhancing scalability, reducing contamination risks, and ensuring clinical trial readiness. This case study highlights innovative solutions that streamline complex workflows for regulatory and clinical success.
This white paper demonstrates the validation of an impedance-based potency assay for CAR T cells, showing high repeatability and precision across replicates, operators, and days. Using the Maestro Z™ platform, the assay accurately quantifies CAR T efficacy in a real-time, non-invasive manner, supporting reliable immunotherapy product evaluation.
Explore an innovative feeder cell–free protocol for efficient expansion of Vγ9Vδ2 T cells following αβ T cell depletion, coupled with high CAR transduction efficiency using the BaEV pseudotype and Vectofusin®-1. The integration of CAR constructs further amplifies the natural cytotoxicity of Vγ9Vδ2 T cells, demonstrating a clinically viable approach within closed systems like the CliniMACS Prodigy® for scalable production.
CGT experiments are complex and require high standards for approval and translation into routine clinical use. Read how you can use software, tools such as the MACSQuant® Analyzer, and the tips provided here to save time, reduce potential problems, and improve the results of your CGT experiments.
